Balancing Health Medical Center: Compounded Treatments

The following compounded medications and peptide therapies are available through Balancing Health Medical Center. These treatments are formulated by licensed compounding pharmacies based on specific practitioner prescriptions. All treatments require a comprehensive medical evaluation, relevant laboratory testing, and a valid prescription from one of our healthcare providers.

Compounded NAD+

Classification: Coenzyme Format: Compounded injectable solution

NAD+ (Nicotinamide Adenine Dinucleotide) is a naturally occurring coenzyme found in all living cells, essential for fundamental biological processes including cellular energy (ATP) production and mitochondrial function.

• Indications: Utilized in metabolic support protocols to address cellular energy deficits, support metabolic function, and assist in cellular repair processes.

• Administration: Typically administered via subcutaneous (SubQ) injection or intravenous (IV) infusion, depending on the prescribed clinical protocol.

• Monitoring: Monitored via patient-reported outcomes regarding energy levels and standard metabolic panels.

Compounded Sermorelin

Classification: Growth Hormone-Releasing Hormone (GHRH) Analogue Format: Compounded injectable lyophilized powder (requires reconstitution)

Sermorelin is a synthetic peptide chain consisting of 29 amino acids. It functions as a secretagogue, binding to the GHRH receptor in the anterior pituitary gland to stimulate the natural production and secretion of endogenous human growth hormone (hGH).

• Indications: Prescribed for adult patients in hormone optimization protocols to support metabolic function, improve body composition, and assist in tissue recovery without suppressing natural pituitary function.

• Administration: Administered via subcutaneous (SubQ) injection. Dosing is typically scheduled once daily, immediately prior to sleep, to mimic natural hormonal pulses.

• Monitoring: Requires baseline and ongoing laboratory evaluation of IGF-1 (Insulin-like Growth Factor 1) levels, alongside general metabolic screening.

Compounded Glutathione

Classification: Antioxidant Format: Compounded injectable solution

Glutathione is a tripeptide composed of three amino acids: glutamine, glycine, and cysteine. It acts as the body's primary intracellular antioxidant, playing a critical role in neutralizing free radicals, reactive oxygen species, and supporting phase II liver detoxification.

• Indications: Prescribed for clinical protocols targeting systemic oxidative stress, immune system support, and hepatic (liver) detoxification.

• Administration: Commonly administered via intramuscular (IM) injection, subcutaneous (SubQ) injection, or as an intravenous (IV) push.

• Monitoring: Assessed through patient clinical response and periodic liver function tests (LFTs) if indicated by the provider.

Compounded Semaglutide

Classification: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Format: Compounded injectable solution

Compounded semaglutide utilizes the active pharmaceutical ingredient semaglutide to mimic the endogenous GLP-1 hormone. It mechanisms include stimulating insulin secretion, inhibiting glucagon release, slowing gastric emptying, and targeting appetite-regulation centers in the brain.

• Indications: Prescribed as part of a comprehensive medical weight management program for patients meeting specific Body Mass Index (BMI) criteria, or for glycemic control in insulin-resistant patients.

• Administration: Administered via subcutaneous (SubQ) injection. The medication is dosed on a strict once-weekly schedule, with gradual dosage titration to mitigate gastrointestinal side effects.

• Monitoring: Requires routine monitoring of body weight, body composition, fasting blood glucose, HbA1c, and comprehensive metabolic panels.

Compounded Tirzepatide

Classification: Dual GLP-1 and GIP Receptor Agonist Format: Compounded injectable solution

Compounded tirzepatide utilizes the active pharmaceutical ingredient tirzepatide. It is a dual-acting peptide that activates both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, creating a synergistic effect on blood glucose regulation and appetite suppression.

• Indications: Prescribed for advanced medical weight management and metabolic regulation in patients requiring a dual-agonist approach.

• Administration: Administered via subcutaneous (SubQ) injection on a once-weekly schedule. Dosage is titrated upward over several months based on patient tolerance and clinical response.

• Monitoring: Requires strict baseline and continuous monitoring of patient weight, gastrointestinal tolerance, fasting blood glucose, HbA1c, and lipid panels.

Medical Disclaimer: The information provided on this page is for general informational purposes only and does not constitute medical advice. The medications listed are custom-compounded by state-licensed compounding pharmacies pursuant to a patient-specific prescription. Eligibility for any treatment is determined solely by a medical provider after a formal clinical evaluation.